dc.creatorCastillo Henríquez, Luis
dc.creatorMadrigal Redondo, German
dc.creatorVargas Zúñiga, Rolando
dc.creatorCarazo Berrocal, Gustavo
dc.date.accessioned2020-04-28T19:34:28Z
dc.date.accessioned2022-10-20T02:04:29Z
dc.date.available2020-04-28T19:34:28Z
dc.date.available2022-10-20T02:04:29Z
dc.date.created2020-04-28T19:34:28Z
dc.date.issued2018
dc.identifierhttp://jddtonline.info/index.php/jddt/article/view/1727
dc.identifier2250-1177
dc.identifierhttps://hdl.handle.net/10669/80935
dc.identifier10.22270/jddt.v8i3.1727
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4544756
dc.description.abstractIt is essential to guarantee physico-chemical compatibility between the active pharmaceutical ingredient (API) and the components that are planned to be used in the development of a pharmaceutical formulation. A successful compatibility study allows distinguishing between the excipients that can be used and those that may represent a risk in the quality, safety and efficacy of the medication. The present study focuses on the identification of possible incompatibilities between Rupatadine fumarate and the excipients of three formulation prototypes for the development of API´s 10 mg tablets. Samples of each raw material, placebos and preformulation mixtures were analyzed by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), X-ray diffraction (XDR) and infrared spectroscopy (IRS). The results obtained were analyzed and contrasted with the literature. Based on these, it is demonstrated that the excipients used along with the API do not generate problems in terms of compatibility, as there are no chemical changes in the drug.
dc.languageen_US
dc.sourceJournal of Drug Delivery and Therapeutics, vol.8(3), pp.42-54
dc.subjectActive pharmaceutical ingredient
dc.subjectChemical incompatibility
dc.subjectCompatibility study
dc.subjectDifferential scanning calorimetry
dc.subjectInfrared spectroscopy
dc.subjectPreformulation powder mixtures
dc.subjectRupatadine fumarate
dc.subjectThermal analysis
dc.titleCombined use of DSC, TGA, XDR and NIR in the compatibility study of preformulation mixtures for the development of 10 mg tablets of Rupatadine Fumarate
dc.typeartículo científico


Este ítem pertenece a la siguiente institución